36,517 results match your criteria endometrial carcinoma


FOXA1 is associated with high tumor grade, myometrial invasion and lymph node invasion in endometrial endometrioid carcinoma.

Ginekol Pol 2021 Apr 12. Epub 2021 Apr 12.

University of Health Sciences, Antalya Education and Research Hospital, Department of Pathology, Antalya, Turkey.

Objectives: FOXA1 expression has been demonstrated in several hormone-dependent cancers. However, data are limited concerning the role of FOXA1 in endometrial cancers. The present study aimed to investigate FOXA1 expression via the microarray technique in benign hyperplasia, endometrial intraepithelial neoplasia, and endometrial endometrioid carcinoma. Read More

View Article and Full-Text PDF

Dermatopontin as a potential pathogenic factor in endometrial cancer.

Oncol Lett 2021 May 22;21(5):408. Epub 2021 Mar 22.

Department of Obstetrics and Gynaecology, Xuzhou Central Hospital, Affiliated Xuzhou Clinical College of Xuzhou Medical University, Xuzhou, Jiangsu 221004, P.R. China.

The present study aimed to determine the differential expression profiles of proteins in endometrial carcinoma and to screen the proteins associated with the occurrence and development of endometrial cancer (EC). In total, 15 samples of human EC and paracancerous tissues were selected for proteomic analysis using a label-free quantification method based on liquid chromatography-tandem mass spectrometry. The differential proteins were analysed using bioinformatics and verified using reverse transcription-quantitative PCR (RT-qPCR) and western blotting. Read More

View Article and Full-Text PDF

Cytonuclear Estrogen Receptor Alpha Regulates Proliferation and Migration of Endometrial Carcinoma Cells.

Tokai J Exp Clin Med 2021 Apr 20;46(1):7-16. Epub 2021 Apr 20.

Department of Anatomy, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.

Objective: The effects of estrogen on cells are mediated by the estrogen receptor α (ERα) which localizes at the peri-membrane, cytoplasm, and the nucleus of cells. Therefore, we intended to investigate how cytonuclear ERα plays its roles in different cellular activities.

Methods: We used amino acid substituted ERα that localized at the cytoplasm and nucleus but has no direct DNA-binding activities. Read More

View Article and Full-Text PDF

Differential Expression of Androgen Receptor in Type I and Type II Endometrial Carcinomas: A Clinicopathological Analysis and Correlation with Outcome.

Oman Med J 2021 Mar 31;36(2):e245. Epub 2021 Mar 31.

Faculty of Medicine,University of Jordan, Amman, Jordan.

Objectives: Endometrial carcinomas (EC) are the most common gynecological malignancies and are conventionally divided into type I and type II due to diagnostic and prognostic considerations. Female hormone expression in EC is extensively studied; however, data about androgen receptor (AR) expression in EC are sparse. We aimed to study AR expression in different types of EC at our institute and whether it had an impact on patient outcomes. Read More

View Article and Full-Text PDF

Chemotherapy response score as a prognostic tool in patients with advanced stage endometrial carcinoma treated with neoadjuvant chemotherapy.

Int J Gynecol Cancer 2021 Apr 8. Epub 2021 Apr 8.

Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois, USA

Background: Chemotherapy response score (CRS) applied to interval debulking specimens quantifies histopathologic response to neoadjuvant chemotherapy in patients with advanced ovarian carcinoma and correlates with progression-free and overall survival.

Objective: To investigate whether the chemotherapy response score could be applied to interval debulking specimens in patients with advanced endometrial carcinoma and be a prognostic indicator.

Methods: The study included patients with clinical stage III-IV endometrial carcinoma who received neoadjuvant chemotherapy followed by interval debulking surgery. Read More

View Article and Full-Text PDF

Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis.

Diagn Pathol 2021 Apr 8;16(1):28. Epub 2021 Apr 8.

Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan.

Background: This study aimed to investigate the association between clinicopathologic factors, mesothelin, and cancer antigen (CA) 125 in endometrial carcinoma.

Methods: Between 1989 and 2017, patients with endometrial carcinoma who underwent total hysterectomy and bilateral salpingo-oophorectomy at our hospital were identified. The association between either or both immunochemical expression of mesothelin and CA125 and clinicopathological features were retrospectively examined. Read More

View Article and Full-Text PDF

Value of preoperative staging of endometrial carcinoma with contrast-enhanced ultrasonography: A PRISMA compliant meta-analysis.

Medicine (Baltimore) 2021 Apr;100(14):e25434

Department of Ultrasound, Yiwu Maternity and Children Hospital, Yiwu, Jinhua, Zhejiang, China.

Introduction: Endometrial carcinoma (EC) is the most common gynecologic carcinoma in developed countries and accounts for nearly 5% of carcinoma cases and more than 2% of deaths due to female carcinomas worldwide. Because of this reported risk, it is very important to diagnose and stage it accurately. Therefore, we investigated the staging accuracy of EC with contrast-enhanced ultrasonography (CEUS). Read More

View Article and Full-Text PDF

[Application of artificial intelligence-assisted diagnosis for cervical liquid-based thin-layer cytology].

Zhonghua Bing Li Xue Za Zhi 2021 Apr;50(4):333-338

Department of Pathology, Nanfang Hospital and Basic Medical College, Southern Medical University, Guangzhou 510515, China.

To explore the application value of artificial intelligence-assisted diagnosis system for TBS report in cervical cancer screening. A total of 16 317 clinical samples and related data of cervical liquid-based thin-layer cell smears, which were obtained from July 2020 to September 2020, were collected from Southern Hospital, Guangzhou Huayin Medical Inspection Center, Shenzhen Bao'an People's Hospital(Group) and Changsha Yuan'an Biotechnology Co., Ltd. Read More

View Article and Full-Text PDF

The use of hysteroscopic endometrectomy in the conservative treatment of early endometrial cancer and atypical hyperplasia in fertile women.

Arch Gynecol Obstet 2021 Apr 8. Epub 2021 Apr 8.

Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

Objective: To illustrate the effectiveness of hysteroscopic endometrial resection in conservative treatment of early endometrial cancer/atypical hyperplasia in women of reproductive age.

Methods: Review of outcomes of women of reproductive age who underwent fertility sparing treatment (hysteroscopic superficial endometrectomy followed by progestin therapy) in early endometrial cancer.

Results: Eight women with Stage I endometrial cancer and three with atypical endometrial hyperplasia underwent hysteroscopic superficial endometrial resection, followed by 1-year treatment with oral megestrol acetate. Read More

View Article and Full-Text PDF

Laparoscopic vs. robotic-assisted laparoscopy in endometrial cancer staging: large retrospective single-institution study.

J Gynecol Oncol 2021 May;32(3):e45

Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Roma, Italy.

Objective: The aim of this study is to analyze and draw the potential differences between the robotic-assisted surgery (RS) and the laparoscopy (LPS) in endometrial cancer staging.

Methods: In this single-institution retrospective study we enrolled 1,221 consecutive clinical stage I-III endometrial cancer patients undergone minimally invasive surgical staging. We compared patients treated by LPS and by RS, on the basis of perioperative and oncological outcomes (disease-free survival [DFS] and overall survival [OS]). Read More

View Article and Full-Text PDF

Hsa_circ_0001610 knockdown modulates miR-646-STAT3 axis to suppress endometrial carcinoma progression.

J Gene Med 2021 Apr 6:e3337. Epub 2021 Apr 6.

Department of Neurosurgery, The Affiliated Huai'an Hospital of Xuzhou Medical University, The Second People's Hospital of Huai'an, Huai'an, China.

Background: Endometrial carcinoma (EC) development is associated with dysregulated circular RNA profiles. The purpose of the current research is to study the role and mechanism of hsa_circ_0001610 (circ_0001610) in EC progression.

Methods: Circ_0001610, microRNA (miR)-646 and signal transducer and activator of transcription 3 (STAT3) expression levels were measured in EC. Read More

View Article and Full-Text PDF

[Current WHO classification of the female genitals : Many new things, but also some old].

Pathologe 2021 Apr 6. Epub 2021 Apr 6.

Arbeitsgruppe Mamma‑, Gynäko- & Perinatalpathologie, Institut für Pathologie, Universitätsklinikum Leipzig AöR, Leipzig, Deutschland.

The new WHO classification of tumors of the female genitalia entails some changes, especially those of prognostic and therapeutic relevance: there is a return to the term borderline tumor. Implants are again subdivided into noninvasive implants of the epithelial or desmoplastic type as before. Invasive extraovarian implants are classified as low-grade serous carcinoma (LGSC). Read More

View Article and Full-Text PDF

Adjuvant effects of chemotherapeutics and Metformin on MFE-319 endometrial carcinoma cell line.

Rom J Morphol Embryol 2020 Jul-Sep;61(3):707-714

Department of Histology and Embryology, Faculty of Medicine, Nigde Omer Halisdemir University, Nigde, Turkey;

We aimed to investigate the cytotoxicity of Metformin, Cisplatin, and Paclitaxel on MFE-319 endometrial carcinoma cell line using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and immunocytochemistry assays. Half maximal inhibitory concentration (IC50) doses of three drugs alone and in the dual combinations were applied to the cells. Immunocytochemical method was performed for the cell survival and for phosphatidylinositol 3-kinase (PI3K), phosphorylated extracellular regulated kinases (pErk)-1∕2, Akt-1, phosphorylated Akt (pAkt)-1∕2∕3 cell growth markers and angiogenic vascular endothelial growth factor (VEGF). Read More

View Article and Full-Text PDF

Prominent decidualization following progestin treatment for endometrial hyperplasia and carcinoma as a mimic of large residual tumor: A cautionary tale.

Gynecol Oncol Rep 2021 May 16;36:100747. Epub 2021 Mar 16.

University of Wisconsin Carbone Cancer Center, USA.

Objective: Progestin-based therapy is common for patients with endometrial neoplasia who desire fertility preservation, but some patients ultimately require surgery. Intraoperative assessment, which can use gross lesion size, may impact the extent of surgery performed. We sought to characterize the extent to which grossly identified lesions in the setting of progestin therapy correspond to microscopic findings. Read More

View Article and Full-Text PDF

Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.

Gynecol Oncol 2021 Mar 31. Epub 2021 Mar 31.

Department of Public Health, University of Naples Federico II, Naples, Italy.

Objective: Deficient expression of mismatch repair proteins (MMR) has been suggested to be a predictor of resistance of atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) to conservative treatment.

Aims: To assess the predictive value of MMR immunohistochemistry in patients conservatively treated for AEH and EEC, and to calculate its predictive accuracy.

Materials And Methods: All patients with AEH or EEC conservatively treated with hysteroscopic resection plus progestins in two referral centers from January 2004 to July 2019 were retrospectively assessed. Read More

View Article and Full-Text PDF

Adlay Testa ( L. var. Stapf.) Ethanolic Extract and Its Active Components Exert Anti-Proliferative Effects on Endometrial Cancer Cells via Cell Cycle Arrest.

Molecules 2021 Mar 31;26(7). Epub 2021 Mar 31.

School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 110301, Taiwan.

Endometrial cancer is the most common malignant tumors of gynecologic neoplasms in Western society. In recent years, the incidence of endometrial cancer has increased, and it has become the third most common female gynecological cancer (after ovarian and cervical cancer) in Taiwan. Adlay ( L. Read More

View Article and Full-Text PDF

The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions.

Cancers (Basel) 2021 Mar 23;13(6). Epub 2021 Mar 23.

Department of Gynecology and Obstetrics, University Medical Center Mainz, 55131 Mainz, Germany.

Adjuvant treatment decisions for endometrial cancer (EC) are based on stage, the histological grade of differentiation, histological subtype, and few histopathological markers. The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) identified four risk groups of EC patients using a combination of immunohistochemistry and mutation analysis: Polymerase Epsilon exonuclease domain mutated (POLE EDM), mismatch repair deficient (MMRd), p53 wild-type/copy-number-low (p53 wt), and p53-mutated/copy-number-high (p53 abn). Patients allocated to the POLE or abnormal p53 expression subtype are faced with a significantly altered outcome possibly requiring a modified adjuvant treatment decision. Read More

View Article and Full-Text PDF

Update on Endometrial Stromal Tumours of the Uterus.

Diagnostics (Basel) 2021 Mar 3;11(3). Epub 2021 Mar 3.

School of Pharmacy and Biomedical Sciences, University of Portsmouth, St. Michaels Building, White Swan Road, Portsmouth PO1 2DT, UK.

Endometrial stromal tumours (ESTs) are rare, intriguing uterine mesenchymal neoplasms with variegated histopathological, immunohistochemical and molecular characteristics. Morphologically, ESTs resemble endometrial stromal cells in the proliferative phase of the menstrual cycle. In 1966 Norris and Taylor classified ESTs into benign and malignant categories according to the mitotic count. Read More

View Article and Full-Text PDF

The Influence of Biologically Active Substances Secreted by the Adipose Tissue on Endometrial Cancer.

Diagnostics (Basel) 2021 Mar 11;11(3). Epub 2021 Mar 11.

Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Al. Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland.

Endometrial cancer is one of the most frequently diagnosed gynecological neoplasms in developed countries and its incidence is rising. Usually, it is diagnosed in the early stages of the disease and has a good prognosis; however, in later stages, the rate of recurrence reaches up to 60%. The discrepancy in relapse rates is due to the heterogeneity of the group related to the presence of prognostic factors affecting survival parameters. Read More

View Article and Full-Text PDF

Giant port-site recurrence after laparoscopic-staging for endometrial cancer.

Int J Gynecol Cancer 2021 Apr;31(4):641

Medical Oncology, Clinica Universidad de Navarra, Madrid, Madrid, Spain.

View Article and Full-Text PDF

Familial burden and other clinical factors associated with various types of cancer in individuals with Lynch syndrome.

Gastroenterology 2021 Mar 25. Epub 2021 Mar 25.

Dana-Farber Cancer Institute, Boston, MA 02215; Harvard Medical School, Boston, MA 02215; Brigham & Women's Hospital, Boston, MA 02215. Electronic address:

Background & Aims: Lynch syndrome (LS) is associated with increased risks of various gastrointestinal, gynecologic, genitourinary, and other cancers. Many clinical practice guidelines recommend that LS carriers' screening strategies be devised based on their family history of various cancers, in addition to age-/sex-/gene-specific considerations. The aim of this study was to examine the association between family history and other clinical factors with LS carriers' histories of various cancers. Read More

View Article and Full-Text PDF

Suppression of synuclein gamma inhibits the movability of endometrial carcinoma cells by PI3K/AKT/ERK signaling pathway.

Genes Genomics 2021 Mar 31. Epub 2021 Mar 31.

Research Department, Hangzhou Bio-Science Bio-Tech Co., Ltd., No. 288 Qiuyi Road, Binjiang District, Hangzhou, 310056, Zhejiang, China.

Background: Although overexpression of synuclein gamma (SNCG) has been reported in several cancers, few studies have been performed onSNCG in endometrial carcinomas.

Objective: This study aimed to investigate the role of SNCG in the progression of endometrial carcinoma.

Methods: The expression pattern and function ofSNCG gene were analyzed using the Gene Expression Omnibus (GEO) and Gene Set Enrichment Analysis (GSEA) datasets. Read More

View Article and Full-Text PDF

ER-positive endocervical adenocarcinoma mimicking endometrioid adenocarcinoma in morphology and immunohistochemical profile: A case report of application of HPV RNAscope detection.

Medicine (Baltimore) 2021 Apr;100(13):e24927

Department of Pathology, the Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.

Rationale: Usual-type endocervical adenocarcinoma (ECA), high-risk HPV associated, is the most common type of glandular carcinoma in the endocervix. Mucin-depleted usual-type ECA is 1 end of morphological lineage of usual-type ECA and morphologically may show endometrioid features, which could cause diagnostic challenge with uterine endometrioid adenocarcinoma (EEC) and primary endometrioid ECA, especially in the setting of small biopsy and endocervical curettage (ECC).

Patient Concerns: A 37-year-old women presented with dyspareunia for 1 year, showing atypical glandular cell on a liquid-based Pap TCT examination and positive for HPV16 detection. Read More

View Article and Full-Text PDF

The Impact of Adjuvant Management Strategies on Outcomes in Women With Early Stage Uterine Serous Carcinoma.

Cureus 2021 Feb 23;13(2):e13505. Epub 2021 Feb 23.

Radiation Oncology, Henry Ford Health System, Detroit, USA.

Objective To determine the impact of different adjuvant strategies on outcomes in women with early-stage uterine serous carcinoma (USC). Methods Our retrospective database for women with endometrial carcinoma was queried for women with 2009 International Federation of Gynecology and Obstetrics (FIGO) stages I-II USC who underwent surgical staging between January 1991 and April 2019 followed by adjuvant management (observation, radiation therapy (RT), chemotherapy (CT), or combined modality treatment (CRT)). Chi-square tests were performed to compare differences in outcome by type of adjuvant management. Read More

View Article and Full-Text PDF
February 2021

Preoperative factors of endometrial carcinoma in patients undergoing hysterectomy for atypical endometrial hyperplasia.

J Obstet Gynaecol Can 2021 Mar 27. Epub 2021 Mar 27.

Department of Obstetrics and Gynaecology, Kingston Health Sciences Centre, Kingston, ON. Electronic address:

Objective: To identify clinicopathological preoperative factors associated with concurrent endometrial carcinoma in patients undergoing surgical management of atypical endometrial hyperplasia.

Methods: The records of all patients who underwent hysterectomy for preoperatively diagnosed atypical endometrial hyperplasia at a tertiary care hospital from April 2017 to April 2020 were retrospectively reviewed. Clinicopathological characteristics of patients were extracted. Read More

View Article and Full-Text PDF

Cervical Mesonephric Adenocarcinoma: A Case Report of a Rare Gynecological Tumor from Embryological Remains of the Female Genital Tract.

Rev Bras Ginecol Obstet 2021 Mar 30. Epub 2021 Mar 30.

Department of Obstetrics, Gynecology and Reproductive Medicine, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.

Introduction:  Malignant mesonephric tumors are uncommon in the female genital tract, and they are usually located where embryonic remnants of Wolffian ducts are detected, such as the uterine cervix. The information about these tumors, their treatment protocol, and prognosis are scarce.

Case Report:  A 60-year-old woman with postmenopausal vaginal bleeding was initially diagnosed with endometrial carcinoma. Read More

View Article and Full-Text PDF

BarH-like homeobox 1 induces the progression of cell malignant phenotype in endometrial carcinoma through the regulation of ERK/MEK signaling pathway.

Reprod Biol 2021 Mar 27;21(2):100502. Epub 2021 Mar 27.

Reproductive Medicine Center of Zibo Maternity and Child Health Hospital, Zibo, 255000, PR China. Electronic address:

The aim of this article was to assess whether and how BARX1 affects the progression of malignant phenotype of endometrial carcinoma (EC) cells. BARX1 levels and its prognostic value were evaluated using the EC-related RNA sequence dataset from The Cancer Genome Atlas (TCGA) database. Functional experiments were performed to evaluate the biological roles of BARX1 in EC HEC-1-A and KLE cells by silencing BARX1. Read More

View Article and Full-Text PDF

The Landscape and Prognostic Value of Immune Characteristics in Uterine Corpus Endometrial Cancer.

Biosci Rep 2021 Mar 30. Epub 2021 Mar 30.

Henan Polytechnic University, Jiaozuo, China.

In this study, we explored the clinical and immunological characteristics of 575 uterine corpus endometrial carcinoma (UCEC) samples obtained from The Cancer Genome Atlas (TCGA) using the ESTIMATE and CIBERSORT algorithms. First, Kaplan-Meier and univariate Cox regression analyses indicated that the immune cell score was a prognostic factor for overall survival (OS) and recurrence-free survival (RFS). Multivariate Cox regression analysis further revealed that the immune cell score was an independent prognostic factor for UCEC patients. Read More

View Article and Full-Text PDF

Overexpression of MYBL2 predicts poor prognosis and promotes oncogenesis in endometrial carcinoma.

Eur J Histochem 2021 Mar 30;65(2). Epub 2021 Mar 30.

Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province.

Endometrial cancer (EC) is the most common gynecologic malignancy and still remains clinically challenging. We aimed to explore the potential biomarkers of EC and provide a theoretical basis for early screening and targeted therapy. The available transcriptome data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were analyzed to identify differentially expressed genes. Read More

View Article and Full-Text PDF

HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma.

Int J Gynecol Pathol 2021 Mar 29. Epub 2021 Mar 29.

Departments of Pathology and Laboratory Medicine (A.C., E.N.R., T.S., C.F., P.S.W., S.M.M.G.) Obstetrics and Gynecology (A.A.-N.) Carbone Cancer Center (A.A.-N., P.S.W., S.M.M.G.) School of Medicine and Public Health (B.S., N.V.), University of Wisconsin-Madison Department of Pathology, Yale University School of Medicine, New Haven, Connecticut (P.H., N.B.).

There is increasing evidence that many endometrial cancers (EC) diagnosed as clear cell carcinoma (CCC) have substantial overlap with both serous carcinoma (SC) and endometrioid carcinoma (EmC), not only in terms of morphology and immunophenotype but also by molecular characterization. Now with use of HER2-based therapy in SC, a CCC diagnosis in serous-like tumors has the potential to exclude patients from receiving beneficial therapy. To assess HER2 in CCC in relation to other characteristics, a tissue microarray of archived CCC, EmC, and SC was stained for HER2 alongside a battery of immunostains used in EC. Read More

View Article and Full-Text PDF